Cargando…

The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis

BACKGROUND: To provide real‐world outcomes for the combination of etoposide and platinum as a first‐line treatment for advanced thymic neuroendocrine neoplasms (TNENs). METHODS: Retrospective analysis was performed on patients with advanced TNENs confirmed by pathology who received etoposide combine...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Yelan, Yao, Qifeng, Hao, Yue, Zeng, Xiaohong, Wang, Wenxian, Gu, Xiadong, Xiang, Jing, Sun, Yan, Song, Zhengbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469660/
https://www.ncbi.nlm.nih.gov/pubmed/37351565
http://dx.doi.org/10.1002/cam4.6245
_version_ 1785099491346481152
author Guan, Yelan
Yao, Qifeng
Hao, Yue
Zeng, Xiaohong
Wang, Wenxian
Gu, Xiadong
Xiang, Jing
Sun, Yan
Song, Zhengbo
author_facet Guan, Yelan
Yao, Qifeng
Hao, Yue
Zeng, Xiaohong
Wang, Wenxian
Gu, Xiadong
Xiang, Jing
Sun, Yan
Song, Zhengbo
author_sort Guan, Yelan
collection PubMed
description BACKGROUND: To provide real‐world outcomes for the combination of etoposide and platinum as a first‐line treatment for advanced thymic neuroendocrine neoplasms (TNENs). METHODS: Retrospective analysis was performed on patients with advanced TNENs confirmed by pathology who received etoposide combined with platinum as a first‐line chemotherapy in our institution between 2010 and 2022. RESULTS: A total of 16 patients were included in this study. Twelve patients (75%) received etoposide combined with cisplatin, and four patients (25%) received etoposide combined with carboplatin. Efficacy was evaluated in all patients, with an objective response rate of 31.3%. One patient achieved a complete response, four achieved a partial response, and in eight patients the disease remained stable; the disease control rate was 81.3%. The median progression‐free survival (PFS) was 7.2 months with a 95% confidence interval (CI) of 2.1–12.3 months. The median overall survival (OS) was 50.4 months with a 95% CI of 32.1–68.8 months. No significant difference in efficacy was observed between the treatment groups with regards to PFS (p = 0.095) and OS (p = 0.061). Treatment‐related adverse events were observed in all 12 patients when evaluated for toxicity, manifesting as hematologic toxicity. Grade 3–4 bone marrow suppression occurred in six patients (50%). No treatment‐related deaths were recorded. CONCLUSION: This retrospective analysis, conducted in a real‐life setting, suggests that the combination of etoposide and platinum has a promising anti‐tumor activity in advanced TNENs, with a clinically significant overall response rate.
format Online
Article
Text
id pubmed-10469660
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104696602023-09-01 The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis Guan, Yelan Yao, Qifeng Hao, Yue Zeng, Xiaohong Wang, Wenxian Gu, Xiadong Xiang, Jing Sun, Yan Song, Zhengbo Cancer Med RESEARCH ARTICLES BACKGROUND: To provide real‐world outcomes for the combination of etoposide and platinum as a first‐line treatment for advanced thymic neuroendocrine neoplasms (TNENs). METHODS: Retrospective analysis was performed on patients with advanced TNENs confirmed by pathology who received etoposide combined with platinum as a first‐line chemotherapy in our institution between 2010 and 2022. RESULTS: A total of 16 patients were included in this study. Twelve patients (75%) received etoposide combined with cisplatin, and four patients (25%) received etoposide combined with carboplatin. Efficacy was evaluated in all patients, with an objective response rate of 31.3%. One patient achieved a complete response, four achieved a partial response, and in eight patients the disease remained stable; the disease control rate was 81.3%. The median progression‐free survival (PFS) was 7.2 months with a 95% confidence interval (CI) of 2.1–12.3 months. The median overall survival (OS) was 50.4 months with a 95% CI of 32.1–68.8 months. No significant difference in efficacy was observed between the treatment groups with regards to PFS (p = 0.095) and OS (p = 0.061). Treatment‐related adverse events were observed in all 12 patients when evaluated for toxicity, manifesting as hematologic toxicity. Grade 3–4 bone marrow suppression occurred in six patients (50%). No treatment‐related deaths were recorded. CONCLUSION: This retrospective analysis, conducted in a real‐life setting, suggests that the combination of etoposide and platinum has a promising anti‐tumor activity in advanced TNENs, with a clinically significant overall response rate. John Wiley and Sons Inc. 2023-06-23 /pmc/articles/PMC10469660/ /pubmed/37351565 http://dx.doi.org/10.1002/cam4.6245 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Guan, Yelan
Yao, Qifeng
Hao, Yue
Zeng, Xiaohong
Wang, Wenxian
Gu, Xiadong
Xiang, Jing
Sun, Yan
Song, Zhengbo
The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis
title The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis
title_full The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis
title_fullStr The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis
title_full_unstemmed The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis
title_short The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis
title_sort combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: a retrospective analysis
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469660/
https://www.ncbi.nlm.nih.gov/pubmed/37351565
http://dx.doi.org/10.1002/cam4.6245
work_keys_str_mv AT guanyelan thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis
AT yaoqifeng thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis
AT haoyue thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis
AT zengxiaohong thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis
AT wangwenxian thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis
AT guxiadong thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis
AT xiangjing thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis
AT sunyan thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis
AT songzhengbo thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis
AT guanyelan combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis
AT yaoqifeng combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis
AT haoyue combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis
AT zengxiaohong combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis
AT wangwenxian combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis
AT guxiadong combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis
AT xiangjing combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis
AT sunyan combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis
AT songzhengbo combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis